Key Highlights
- Lipogems announces Corporate Circle Membership with Crohn’s & Colitis Foundation.
- Aims to raise awareness of Lipogems system among IBD patients and clinicians.
- Carl Llewellyn, CEO of Lipogems USA, highlights the potential to heal tissue using patients’ own Microfat.
- Elise Ambrose of the Crohn’s & Colitis Foundation supports partnership for innovative patient solutions.
Source: PR Newswire
Notable Quotes
- “Our hope is to heal patients’ tissue using their own Microfat and prevent these patients from receiving ileostomy procedures that may limit them from freely enjoying their lives.” — Carl Llewellyn, CEO and President at Lipogems USA
- “This partnership with Lipogems will enhance awareness of this technology among providers and patients who may have tried other options with limited relief.” — Elise Ambrose, Associate Vice-President, Business Development at Crohn’s & Colitis Foundation
SoHC's Take
The partnership between Lipogems and the Crohn’s & Colitis Foundation marks a significant step in advancing treatment options for IBD patients. By leveraging the Lipogems system, which utilizes patients’ own Microfat to heal tissue, this collaboration has the potential to significantly improve patient outcomes and reduce the need for invasive procedures. The commitment from both organizations to raise awareness and educate clinicians and patients is commendable, and it is anticipated that this initiative will pave the way for broader acceptance and application of innovative adipose tissue solutions in the medical community.
